A phase 4 single-arm open-label clinical study of pembrolizumab (MK-3475) to evaluate the efficacy and safety of MK-3475 plus carboplatin and paclitaxel as first-line treatment of recurrent/ metastatic head and neck squamous cell carcinoma.

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Head And Neck Squamous Cell Carcinoma
  • Age: Between 18 - 120 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Has histologically or cytologically-confirmed diagnosis of R/M HNSCC that is considered incurable by local therapies and has not had prior systemic therapy administered in the recurrent or metastatic setting. 2) Has a primary tumor location of oropharynx, oral cavity, hypopharynx, or larynx. 3) Does NOT have a primary tumor site of nasopharynx (any histology). 4) Does NOT have an unknown primary tumor.

You may not be eligible for this study if the following are true:

  • 1) Medical Conditions - Has had an allogenic tissue/solid organ transplant. 2) Has disease that is suitable for local therapy administered with curative intent. 3) Has progressive disease within 6 months of completion of curatively intended systemic treatment for locoregionally advanced HNSCC. 4) Has a life expectancy of less than 3 months and/or has rapidly progressing disease (e.g. tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.